Browse by author
Lookup NU author(s): Dr Ian HardcastleORCiD, Emeritus Professor Bernard Golding, Professor Roger Griffin
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Cyclin-dependent kinases (cdks) play a pivotal role in controlling progression through the cell cycle. The complex mechanisms that control cdks have been elucidated and, in the case of cdk2, explained with reference to X-ray crystal structures of the catalytically active and inactive kinase. Deregulation of the cell cycle is commonly observed in cancer, so cdks are potential targets for experimental therapeutic agents. A number of distinct structural classes of cdk inhibitors have been discovered. Good selectivity among these ATP competitive inhibitors for cdks over other kinases has been established, and selectivity between individual cdks is often observed. The crystal structures of a number of key inhibitors bound to cdk2 can be used to explain the observed structure-activity relationships within the compound series and to guide the design of more potent inhibitors.
Author(s): Hardcastle IR, Golding BT, Griffin RJ
Publication type: Review
Publication status: Published
Journal: Annual Review of Pharmacology and Toxicology
Year: 2002
Volume: 42
Pages: 325-348
ISSN (print): 0362-1642
ISSN (electronic): 1545-4304
URL: http://dx.doi.org/10.1146/annurev.pharmtox.42.090601.125940
DOI: 10.1146/annurev.pharmtox.42.090601.125940
PubMed id: 11807175
